2024年美国临床肿瘤学会（ASCO）年会将于当地时间2024年5月31日至6月4日在美国芝加哥盛大召开。作为肿瘤领域最具权威性的年度盛会，全球肿瘤学领域的多项重磅研究将于此次大会公布结果。
近日，ASCO官网已公布部分研究摘要的标题信息。【肿瘤资讯】特别整理大会的Late-breaking Abstract（LBA）研究信息。本次大会总共包含62项LBA研究，其中包括全体大会（Plenary Session）5项以及各瘤种专场57项LBA研究，详情如下，让我们一睹为快吧！
全体大会（Plenary Session）（5项）
摘要号：LBA1
Prospective randomized multicenter phase III trial comparing perioperative chemotherapy (FLOT protocol) to neoadjuvant chemoradiation (CROSS protocol) in patients with adenocarcinoma of the esophagus (ESOPEC trial).
ESPOC研究：比较食管腺癌患者围手术期化疗（FLOT方案）与新辅助放化疗（CROSS方案）的前瞻性随机多中心III期研究
摘要号：LBA2
Neoadjuvant nivolumab plus ipilimumab versus adjuvant nivolumab in macroscopic, resectable stage III melanoma: The phase 3 NADINA trial.
3期NADINA研究：新辅助纳武利尤单抗 + 伊匹木单抗与辅助纳武利尤单抗治疗肉眼可见的可切除III期黑色素瘤
摘要号：LBA3
Comparative effectiveness trial of early palliative care delivered via telehealth versus in person among patients with advanced lung cancer.
晚期肺癌患者通过远程医疗与亲自进行早期姑息治疗的比较有效性试验
摘要号：LBA4
Osimertinib (osi) after definitive chemoradiotherapy (CRT) in patients (pts) with unresectable stage (stg) III epidermal growth factor receptor-mutated (EGFRm) NSCLC: Primary results of the phase 3 LAURA study.
3期LAURA研究主要结果：不可切除的III期表皮生长因子受体突变型（EGFRm）NSCLC患者在确定性放化疗（CRT）后接受奥希替尼（osi）治疗
摘要号：LBA5
ADRIATIC: durvalumab (D) as consolidation treatment (tx) for patients (pts) with limited-stage small-cell lung cancer (LS-SCLC).
ADRIATIC研究：度伐利尤单抗（D）作为局限期小细胞肺癌（LS-SCLC）患者（pts）的巩固治疗（tx）。
以下将分瘤种介绍不同Session的LBA摘要内容。
肺癌（8项）
摘要号：LBA8002
BEAT-meso: A randomized phase III study of bevacizumab (B) and standard chemotherapy (C) with or without atezolizumab (A), as first-line treatment (TX) for advanced pleural mesothelioma (PM)—Results from the ETOP 13-18 trial.
BEAT-meso：贝伐珠单抗（B）和标准化疗（C）联合或不联合阿替利珠单抗（A）作为晚期胸膜间皮瘤（PM）一线治疗（TX）的随机III期研究-ETOP 13-18试验结果。
摘要号：LBA8500
Sacituzumab govitecan (SG) vs docetaxel (doc) in patients (pts) with metastatic non-small cell lung cancer (mNSCLC) previously treated with platinum (PT)-based chemotherapy (chemo) and PD(L)-1inhibitors (IO): Primary results from the phase 3 EVOKE-01 study.
III期EVOKE-01研究的主要结果：Sacituzumab govitecan（SG）与多西他赛（doc）在既往接受过含铂（PT）化疗（化疗）和PD（L）-1抑制剂（IO）治疗的转移性非小细胞肺癌（mNSCLC）患者（pts）中的比较
摘要号：LBA8505
Subcutaneous amivantamab vs intravenous amivantamab, both in combination with lazertinib, in refractory EGFR-mutated, advanced non-small cell lung cancer (NSCLC): Primary results, including overall survival (OS), from the global, phase 3, randomized controlled PALOMA-3 trial.
皮下注射amivantamab与静脉注射amivantamab联合lazertinib治疗难治性EGFR突变的晚期非小细胞肺癌（NSCLC）的比较：来自全球3期随机对照PALOMA-3试验的主要结果，包括总生存期（OS）
摘要号：LBA8503
Lorlatinib vs crizotinib in treatment-naïve patients with advanced ALK+ non-small cell lung cancer: 5-year progression-free survival and safety from the CROWN study.
CROWN研究的5年无进展生存期和安全性结果：洛拉替尼对比克唑替尼在初治晚期ALK+非小细胞肺癌患者中的应用
摘要号：LBA8007
Clinical outcomes with perioperative nivolumab (NIVO) by nodal status among patients (pts) with stage III resectable NSCLC: Results from the phase 3 CheckMate 77T study.
3期CheckMate 77T研究结果：III期可切除NSCLC患者（pts）中按淋巴结状态显示的围手术期纳武利尤单抗（NIVO）的临床结局
摘要号：LBA8010
Neoadjuvant nivolumab (NIVO) + chemotherapy (chemo) vs chemo in patients (pts) with resectable NSCLC: 4-year update from CheckMate 816.
CheckMate 816的4年更新结果：新辅助纳武利尤单抗（NIVO）+化疗（chemo）与化疗在可切除NSCLC患者中的应用
摘要号：LBA8509
KRYSTAL-12: Phase 3 study of adagrasib versus docetaxel in patients with previously treated advanced/metastatic non-small cell lung cancer (NSCLC) harboring a KRASG12C mutation.
III期KRYSTAL-12研究：在既往接受过治疗的携带KRASG 12 C突变的晚期/转移性非小细胞肺癌（NSCLC）患者中比较adagrasib与多西他赛
摘要号：LBA8511
KROCUS: A phase II study investigating the efficacy and safety of fulzerasib (GFH925) in combination with cetuximab in patients with previously untreated advanced KRAS G12C mutated NSCLC.
II期KROCUS研究：考察fulzerasib（GFH925）联合西妥昔单抗治疗既往未经治疗的晚期KRAS G12C突变NSCLC患者的疗效和安全性
乳腺癌（8项）
摘要号：LBA1001
Abemaciclib plus fulvestrant vs fulvestrant alone for HR+, HER2- advanced breast cancer following progression on a prior CDK4/6 inhibitor plus endocrine therapy: Primary outcome of the phase 3 postMONARCH trial
Ⅲ期临床试验postMONARCH的主要结局：阿贝西利+氟维司群 vs氟维司群单药治疗既往CDK4/6抑制剂联合内分泌治疗后进展的HR+、HER2-晚期乳腺癌
摘要号：LBA1004
SACI-IO HR+: A randomized phase II trial of sacituzumab govitecan with or without pembrolizumab in patients with metastatic hormone receptor-positive/HER2-negative breast cancer.
随机II期试验SACI-IO HR+：戈沙妥珠单抗±帕博利珠单抗治疗转移性HR+/HER2-乳腺癌
摘要号：LBA507
Prognostic utility of ctDNA detection in the monarchE trial of adjuvant abemaciclib plus endocrine therapy (ET) in HR+, HER2-, node-positive, high-risk early breast cancer (EBC).
monarchE试验（阿贝西利+内分泌治疗用于HR+、HER2-、淋巴结阳性、高风险早期乳腺癌）中ctDNA检测的预后效用
摘要号：LBA500
A-BRAVE trial: A phase III randomized trial with avelumab in early triple-negative breast cancer with residual disease after neoadjuvant chemotherapy or at high risk after primary surgery and adjuvant chemotherapy.
随机III期A-BRAVE试验：阿维鲁单抗治疗新辅助化疗后有残留病灶或初次手术和辅助化疗后高危的早期TNBC
摘要号：LBA502
A randomized, multicenter, open-label, phase III trial comparing anthracyclines followed by taxane versus anthracyclines followed by taxane plus carboplatin as (neo) adjuvant therapy in patients with early triple-negative breast cancer: Korean Cancer Study Group BR 15-1 PEARLY trial.
一项在早期TNBC患者中比较蒽环类药物序贯紫杉烷与蒽环类药物序贯紫杉烷+卡铂作为（新）辅助治疗的随机、多中心、开放性、III期试验：韩国癌症研究组 BR 15-1 PEARLY 试验
摘要号：LBA1002
Palbociclib plus exemestane with GnRH agonist vs capecitabine in premenopausal patients with HR+/HER2- metastatic breast cancer: Updated survival results of the randomized phase 2 study Young-PEARL.
哌柏西利+依西美坦联合GnRH 激动剂 vs 卡培他滨治疗绝经前HR+/HER2-转移性乳腺癌：Young-PEARL随机 II 期研究更新的生存结局
摘要号：LBA501
Rates of pathologic complete response (pCR) after datopotamab deruxtecan (Dato) plus durvalumab (Durva) in the neoadjuvant setting: Results from the I-SPY2.2 trial.
I-SPY2.2试验：datopotamab deruxtecan（Dato）联合度伐利尤单抗在新辅助治疗中的pCR率
摘要号：LBA509
Rates of pathologic complete response (pCR)after neoadjuvant datopotamab deruxtecan (Dato): Results from the I-SPY2.2 trial.
I-SPY2.2试验结果：datopotamab deruxtecan(Dato)新辅助治疗后的病理学完全缓解 (pCR) 率
消化肿瘤（11项）
摘要号：LBA4001
标题：
Effect of chemotherapy/targeted therapy alone vs. chemotherapy/targeted therapy followed by radical surgical resection on survival and quality of life in patients with limited-metastatic adenocarcinoma of the stomach or esophagogastric junction: The IKF-575/RENAISSANCE phase III trial.
III期IKF-575/RENAISSANCE试验：单纯化疗/靶向治疗与化疗/靶向治疗后行根治性手术切除对胃或食管胃交界处有限转移腺癌患者生存率和生活质量的影响
摘要号：LBA4002
Ramucirumab plus paclitaxel as switch maintenance versus continuation of oxaliplatin-based chemotherapy in patients (pts) with advanced HER2-negative gastric or gastroesophageal junction (GEJ) cancer: the ARMANI phase III trial.
III期ARMANI临床试验：在晚期HER2阴性胃或胃食管交界（GEJ）癌患者中，将雷莫西尤单抗联合紫杉醇作为转换维持治疗与继续使用基于奥沙利铂的化疗进行比较
摘要号：LBA4004
Early results of the PASS-01 trial: Pancreatic adenocarcinoma signature stratification for treatment-01.
PASS-01试验的初步结果：胰腺腺癌标志物分层治疗-01
摘要号：LBA3501
Surgery versus thermal ablation for small-size colorectal liver metastases (COLLISION): An international, multicenter, phase III randomized controlled trial.
手术与热消融治疗小尺寸结直肠肝转移瘤（COLLISION）：一项国际、多中心、III期随机对照试验
摘要号：LBA3504
NEOPRISM-CRC: Neoadjuvant pembrolizumab stratified to tumour mutation burden for high risk stage 2 or stage 3 deficient-MMR/MSI-high colorectal cancer.
NEOPRISM-CRC：帕博利珠单抗新辅助治疗分层肿瘤突变负荷的高风险阶段2或阶段3缺乏MMR/MSI-高结直肠癌
摘要号：LBA3502
Primary outcome analysis of the ORCHESTRA trial: A randomized phase III trial of additional tumor debulking to first-line palliative systemic therapy for patients with multiorgan metastatic colorectal cancer.
ORCHESTRA试验的主要结局分析：一项对多器官转移性结直肠癌患者在一线姑息性全身治疗基础上额外进行肿瘤减瘤的随机III期试验
摘要号：LBA4008
Nivolumab (NIVO) plus ipilimumab (IPI) vs lenvatinib (LEN) or sorafenib (SOR) as first-line treatment for unresectable hepatocellular carcinoma (uHCC): First results from CheckMate 9DW.
CheckMate 9DW研究的首次结果：纳武利尤单抗（NIVO）+伊匹木单抗（IPI）vs Lenvatinib（LEN）或索拉非尼（SOR）作为不可切除肝细胞癌（uHCC）的一线治疗
摘要号：LBA4014
Randomized phase II/III trial of gemcitabine plus nab-paclitaxel versus concurrent chemoradiotherapy with S-1 as neoadjuvant treatment for borderline resectable pancreatic cancer: GABARNANCE study.
GABARNANCE研究：吉西他滨联合白蛋白结合型紫杉醇与同步放化疗联合S-1作为边缘性可切除胰腺癌新辅助治疗的随机II/III期试验
摘要号：LBA3510
Overall survival (OS) of phase 3 CodeBreaK 300 study of sotorasib plus panitumumab (soto+pani) versus investigator’s choice of therapy for KRAS G12C-mutated metastatic colorectal cancer (mCRC).
Sotorasib+帕尼单抗（soto+pani）的3期CodeBreak 300研究与研究者选择的KRAS G12 C突变转移性结直肠癌（mCRC）治疗的总生存期（OS）
摘要号：LBA3511
Total neoadjuvant treatment with long-course radiotherapy versus concurrent chemoradiotherapy in local advanced rectal cancer with high risk factors (TNTCRT): A multicenter, randomized, open-label, phase 3 trial.
局部晚期直肠癌伴高危因素（TNTCRT）患者全程新辅助放疗与同期放化疗的比较：一项多中心、随机、开放标签、III期试验
摘要号：LBA3512
Durable complete responses to PD-1 blockade alone in mismatch repair deficient locally advanced rectal cancer.
错配修复缺陷的局部晚期直肠癌对PD-1阻断剂的持久完全反应
泌尿系统肿瘤（5项）
摘要号：LBA5004
MANCAN2: A multicentre randomised controlled trial of self-help cognitive behavioural therapy (CBT) to manage hot flush and night sweats (HFNS) symptoms in patients with prostate cancer receiving androgen deprivation therapy (ADT).
MANCAN 2：一项在接受雄激素剥夺治疗（ADT）的前列腺癌患者中使用自助认知行为疗法（CBT）管理潮热和盗汗（HFNS）症状的多中心随机对照试验
摘要号：LBA5000
Cabazitaxel with abiraterone versus abiraterone alone randomized trial for extensive disease following docetaxel: The CHAARTED2 trial of the ECOG-ACRIN Cancer Research Group (EA8153).
卡巴他赛联合阿比特龙与单用阿比特龙治疗多西他赛后广泛性疾病的随机试验：ECOG-ACRIN癌症研究组的CHAARTED 2试验（EA8153）
摘要号：LBA5002
A randomized, double-blind, placebo-controlled trial of metformin in reducing progression among men on expectant management for low-risk prostate cancer: The MAST (Metformin Active Surveillance Trial) study.
二甲双胍在低风险前列腺癌期待治疗男性患者中的应用的随机、双盲、安慰剂对照试验：MAST（二甲双胍主动监测试验）研究
摘要号：LBA4517
Perioperative sacituzumab govitecan (SG) alone or in combination with pembrolizumab (Pembro) for patients with muscle-invasive urothelial bladder cancer (MIBC): SURE-01/02 interim results.
SURE-01/02中期结果：围手术期sacituzumab govitecan（SG）单独或联合帕博利珠单抗（Pembro）治疗肌层浸润性尿路上皮膀胱癌（MIBC）患者
摘要号：LBA5014
Blood-based markers of differential efficacy of bipolar androgen therapy and enzalutamide in the randomized TRANSFORMER trial.
随机化TRANSFORMER 试验中双极雄激素治疗和Enzalutamide疗效差异的血液标志物
妇科肿瘤（5项）
摘要号：LBA5505
Omission of lymphadenectomy in patients with advanced epithelial ovarian cancer treated with primary or interval cytoreductive surgery after neoadjuvant chemotherapy: The CARACO phase III randomized trial.
III期随机CARACO试验：晚期上皮性卵巢癌患者在新辅助化疗后接受原发性或间歇性肿瘤细胞减灭术治疗时忽略淋巴结切除术
摘要号：LBA5500
Final results of BrUOG 354: A randomized phase II trial of nivolumab alone or in combination with ipilimumab for people with ovarian and other extra-renal clear cell carcinomas.
随机II期BrUOG 354试验的最终结果：纳武利尤单抗单独或与伊匹木单抗联合治疗卵巢和其他肾外透明细胞癌患者
摘要号：LBA5501
Atezolizumab versus placebo in combination with bevacizumab and non-platinum-based chemotherapy in recurrent ovarian cancer: Final overall and progression-free survival results from the AGO-OVAR 2.29/ENGOT-ov34 study.
AGO-OVAR 2.29/ENGOT-ov 34研究的最终OS和PFS结果：阿替利珠单抗与安慰剂联合贝伐珠单抗和非铂类化疗治疗复发性卵巢癌
摘要号：LBA5516
A phase III randomized, double-blinded, placebo-controlled study of suvemcitug combined with chemotherapy for platinum-resistant ovarian cancer (SCORES).
一项suvemcitug联合化疗治疗铂类耐药卵巢癌的III期、随机、双盲、安慰剂对照研究（SCORES）
摘要号：LBA5515
AXLerate-OC/GOG-3059/ENGOT OV-66: Results of a phase 3, randomized, double-blind, placebo/paclitaxel-controlled study of batiraxcept (AVB-S6-500) in combination with paclitaxel in patients with platinum-resistant recurrent ovarian cancer.
AXLerate-OC/GOG-3059/ENGOT OV-66：一项巴替瑞西普（AVB-S6 -500）联合紫杉醇治疗铂类耐药复发性卵巢癌患者的III期、随机、双盲、安慰剂/紫杉醇对照研究的结果
头颈部肿瘤（4项）
摘要号：LBA6000
Adjuvant PD-1 blockade with camrelizumab in high-risk locoregionally advanced nasopharyngeal carcinoma (DIPPER): A multicenter, open-label, phase 3, randomized controlled trial.
Camrelizumab和PD-1阻断剂辅助治疗高危局部晚期鼻咽癌（DIPPER）：一项多中心、开放标签、3期、随机对照试验
摘要号：LBA6015
PRGN-2012, a novel gorilla adenovirus-based immunotherapy, provides the first treatment that leads to complete and durable responses in recurrent respiratory papillomatosis patients.
一种新型的基于大猩猩腺病毒的免疫疗法——PRGN-2012，首次提供了导致复发性呼吸道乳头状瘤病患者完全和持久反应的治疗方法
摘要号：LBA6018
Covalent FAPI PET enables accurate management of medullary thyroid carcinoma: a prospective single-arm comparative clinical trial.
共价FAPI PET能够准确治疗甲状腺髓样癌：一项前瞻性单臂比较临床试验
摘要号：LBA6019
Phase 3 randomized study for evaluation of physician choice Rx versus best supportive care as second-line or beyond therapy in head and neck cancer with poor performance status.
评价医生选择的Rx与最佳支持性治疗作为体力状态较差的头颈癌二线或超二线治疗的III期随机化研究
黑色素瘤/皮肤癌（5项）
摘要号：LBA9501
Phase 3 study (PIVOTAL) of neoadjuvant intralesional daromun vs. immediate surgery in fully resectable melanoma with regional skin and/or nodal metastases.
在可完全切除的黑色素瘤伴局部皮肤和/或淋巴结转移患者中进行daromun新辅助治疗对比立即手术的III期研究（PIVOTAL）
摘要号：LBA9503
Combination of encorafenib and binimetinib followed by ipilimumab and nivolumab versus ipilimumab and nivolumab in patients with advanced BRAF-V600E/K-mutated melanoma: the primary analysis of an EORTC randomized phase II study (EBIN).
EORTC随机II期研究（EBIN）的主要分析：在晚期BRAF-V600 E/K突变黑色素瘤患者中，联合使用Encorafenib和Binimetinib，随后使用伊匹木单抗和纳武利尤单抗与伊匹木单抗和纳武利尤单抗
摘要号：LBA9512
Individualized neoantigen therapy mRNA-4157 (V940) plus pembrolizumab in resected melanoma: 3-year update from the mRNA-4157-P201 (KEYNOTE-942) trial.
mRNA-4157-P201（KEYNOTE-942）试验的3年更新：个体化新抗原治疗mRNA-4157（V940）联合帕博利珠单抗治疗切除的黑色素瘤
摘要号：LBA9513
Combination or sequence of vemurafenib, cobimetinib, and atezolizumab in high-risk, resectable melanoma (NEO-TIM): Primary results.
维莫非尼、cobimetinib和阿替利珠单抗联合或序贯治疗高危可切除黑色素瘤（NEO-TIM）：初步结果
摘要号：LBA9516
Phase III randomized trial evaluating tilsotolimod in combination with ipilimumab versus ipilimumab alone in patients with advanced refractory melanoma (ILLUMINATE 301).
III期随机试验（ILLUMINATE 301）：评估tilsotolimod 联合伊匹木单抗与伊匹木单抗单独治疗晚期难治性黑色素瘤患者
血液肿瘤（5项）
摘要号：LBA7003
Tucidinostat plus R-CHOP in previously untreated diffuse large B-cell lymphoma with double expression of MYC and BCL2: An interim analysis from the phase III DEB study.
III期DEB研究的中期分析：Tucidinostat联合R-CHOP治疗既往未经治疗的MYC和BCL 2双表达弥漫性大B细胞淋巴瘤
摘要号：LBA7000
Tolerability and efficacy of BrECADD versus BEACOPP in advanced stage classical Hodgkin lymphoma: GHSG HD21, a randomized study.
随机GHSG HD 21研究：BrECADD与BEACOPP在晚期经典霍奇金淋巴瘤中的耐受性和疗效
摘要号：LBA6500
ASC4FIRST, a pivotal phase 3 study of asciminib (ASC) vs investigator-selected tyrosine kinase inhibitors (IS TKIs) in newly diagnosed patients (pts) with chronic myeloid leukemia (CML): Primary results.
ASC4FIRST研究主要结果：一项在新诊断的慢性粒细胞白血病（CML）患者（pts）中比较asciminib（ASC）与促甲状腺激素选择性酪氨酸激酶抑制剂（IS TKI）的关键III期研究
摘要号：LBA6508
Multi-site randomized trial of a collaborative palliative and oncology care model for patients with acute myeloid leukemia (AML) and myelodysplastic syndrome (MDS) receiving non-intensive therapy.
急性髓性白血病（AML）和骨髓增生异常综合征（MDS）患者接受非强化治疗的姑息治疗和肿瘤学协作护理模式的多中心随机试验
摘要号：LBA7005
Brentuximab vedotin in combination with lenalidomide and rituximab in patients with relapsed/refractory diffuse large B-cell lymphoma: Results from the phase 3 ECHELON-3 study.
III期ECHELON-3研究结果：维布妥昔单抗联合来那度胺和利妥昔单抗治疗复发性/难治性弥漫性大B细胞淋巴瘤患者
其它（6项）
摘要号：LBA12006
Primary outcomes of the enhanced, EHR-facilitated cancer symptom control (E2C2) cluster-randomized, stepped wedge, pragmatic trial.
EHR促进的癌症症状控制（E2C2）的增强型、随机分组、阶梯楔形、实用性试验的主要结局
摘要号：LBA12004
Alliance A222001: A randomized, double-blind, placebo controlled phase II study of oxybutynin versus placebo for the treatment of hot flashes in men receiving androgen deprivation therapy.
随机、双盲、安慰剂对照II期Alliance A222001研究：奥昔布宁对比安慰剂治疗接受雄激素剥夺治疗的男性潮热
摘要号：LBA12007
Results from a randomised, open-label trial of a multimodal intervention (exercise, nutrition and anti-inflammatory medication) plus standard care versus standard care alone to attenuate cachexia in patients with advanced cancer undergoing chemotherapy.
一项多模式干预（运动、营养和抗炎药物）加标准治疗与单独标准治疗减轻接受化疗的晚期癌症患者恶病质的随机、开放标签试验的结果
摘要号：LBA12014
Preventive effect of naldemedine for opioid-induced constipation in patients with cancer starting opioids: A multicenter, double-blinded, randomized, placebo-controlled, phase 3 trial.
纳地美定对开始使用阿片类药物的癌症患者阿片类药物诱导的便秘的预防作用：一项多中心，双盲，随机，安慰剂对照，III期试验
摘要号：LBA2509
Atezolizumab in patients (pts) with tumor mutational burden (TMB)–high tumors from the TAPISTRY trial.
TAPISTRY研究：阿替利珠单抗在肿瘤突变负荷（TMB）高肿瘤患者中的应用
摘要号：LBA105
Results from the randomized phase 3 DREAMM-8 study of belantamab mafodotin plus pomalidomide and dexamethasone (BPd) vs pomalidomide plus bortezomib and dexamethasone (PVd) in relapsed/refractory multiple myeloma (RRMM).
随机化3期DREAMM-8研究结果：在复发性/难治性多发性骨髓瘤（RRMM）中，belantamab mafodotin联合泊马度胺和地塞米松（BPd）与泊马度胺联合硼替佐米和地塞米松（PVd）的比较
60余项LBA重磅研究内容，您最期待的是哪些呢？
扫码关注2024ASCO年会专栏，获取更多最新资讯
排版编辑：肿瘤资讯-Nydia
苏公网安备 32059002004080号
